Lawyers suing over the opioid crisis may have overcome a major hurdle in their negotiations for a global settlement, announcing a proposed $26 billion settlement with three major pharmaceutical distributors and Johnson & Johnson.

The announcement, on Thursday, is $4 billion more than a settlement floated earlier this year that reached an impasse over legal fees. Members of the plaintiffs’ executive committee overseeing thousands of lawsuits brought primarily on behalf of cities and counties against opioid companies said they gave “full support” of the revised settlement, which includes a separate fund, paid for by the defendants, for attorney fees.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]